EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide
Molecular & Cellular Proteomics · 2026-11 · 101699
DOI: 10.1016/j.mcpro.2026.101699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-11. Verfasst von Lisenn Lalier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, INSERM, CNRS, CRCI(2)NA, U1307, UMR6075, F-44000 Nantes, France; Institut de Cancérologie de l'Ouest, F-44805 Saint-Herblain, Fran…. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: La Ligue Contre Le Cancer.
Abstract (Originalsprache)
Acquisition of secondary resistance to chemotherapy in cancer cells is an ill-characterized multi-step process. We conducted an unbiased, longitudinal proteomic analysis of U251 glioma cells treated by temozolomide as they transit from drug-sensitive to tolerant and then resistant states. This unprecedented analysis revealed key mitochondrial evolutions throughout the process. Following an early stress substantiated by a transient peak of reactive oxygen species, mitochondrial quality control mechanisms enable emergence of the resistant population. We combined genome editing, targeted protein degradation via PROTAC, and pharmacologic inhibitors to investigate the mechanisms underlying stress resolution both at population and single cell scales (including microscopic evaluation and in-situ proximity ligation assays). These studies unravel a Src-activated EGFR and TBK1 axis that initiates autophagic recycling of mitochondria as a necessary step to the emergence of the resistant population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nantes Université, INSERM, CNRS, CRCI(2)NA, U1307, UMR6075, F-44000 Nantes, France; Institut de Cancérologie de l'Ouest, F-44805 Saint-Herblain, France; SIRIC ILIAD, Nantes, Angers, France. Electronic address: lisenn.la…
- Nantes Université, INSERM, CNRS, CRCI(2)NA, U1307, UMR6075, F-44000 Nantes, France; Plateforme PROT'ICO, Institut de Cancérologie de l'Ouest, F-49000 Angers, France; SIRIC ILIAD, Nantes, Angers, France.
- Nantes Université, INSERM, CNRS, CRCI(2)NA, U1307, UMR6075, F-44000 Nantes, France; Institut de Cancérologie de l'Ouest, F-44805 Saint-Herblain, France; SIRIC ILIAD, Nantes, Angers, France.
- Nantes Université, INSERM, CNRS, CRCI(2)NA, U1307, UMR6075, F-44000 Nantes, France; SIRIC ILIAD, Nantes, Angers, France.
- Plateforme PROT'ICO, Institut de Cancérologie de l'Ouest, F-49000 Angers, France.
Förderung
- La Ligue Contre Le Cancer
Zitieren
APA
Lalier, L., Guillonneau, F., Derrien, J., Saleh, A. E., Cabioch, T., Boissard, A., Henry, C., Barillé-Nion, S., Raimbourg, J., & Juin, P. P. (2026). EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide. Molecular & Cellular Proteomics, 101699. https://doi.org/10.1016/j.mcpro.2026.101699
Vancouver
Lalier L, Guillonneau F, Derrien J, Saleh AE, Cabioch T, Boissard A, et al. EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide. Molecular & Cellular Proteomics. 2026:101699. doi:10.1016/j.mcpro.2026.101699
BibTeX
@article{Lalier2026,
author = {Lalier, Lisenn and Guillonneau, François and Derrien, Jennifer and Saleh, Abed-El-Razzak and Cabioch, Thomas and Boissard, Alice and Henry, Cécile and Barillé-Nion, Sophie and Raimbourg, Judith and Juin, Philippe P},
title = {EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide},
journal = {Molecular & Cellular Proteomics},
year = {2026},
pages = {101699},
doi = {10.1016/j.mcpro.2026.101699}
}
EUVIMED